U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C13H15NO6
Molecular Weight 281.2613
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACETYLSALICYLIC-L-THREONINE ESTER

SMILES

C[C@@H](OC(=O)C1=C(OC(C)=O)C=CC=C1)[C@H](N)C(O)=O

InChI

InChIKey=KUUVQWCRENBXIV-HQJQHLMTSA-N
InChI=1S/C13H15NO6/c1-7(11(14)12(16)17)19-13(18)9-5-3-4-6-10(9)20-8(2)15/h3-7,11H,14H2,1-2H3,(H,16,17)/t7-,11+/m1/s1

HIDE SMILES / InChI

Molecular Formula C13H15NO6
Molecular Weight 281.2613
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 11:36:50 GMT 2023
Edited
by admin
on Sat Dec 16 11:36:50 GMT 2023
Record UNII
362NTC92GU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACETYLSALICYLIC-L-THREONINE ESTER
Common Name English
L-THREONINE, 2-(ACETYLOXY)BENZOATE (ESTER)
Systematic Name English
BENZOIC ACID, 2-(ACETYLOXY)-, (1R,2S)-2-AMINO-2-CARBOXY-1-METHYLETHYL ESTER
Systematic Name English
SPIB-00102
Code English
(2S,3R)-3-(2-ACETOXYBENZOYL)OXY-2-AMINO-BUTANOIC ACID
Systematic Name English
L-THREONINE DERIVATIVE-1
Common Name English
PLATROL
Common Name English
Code System Code Type Description
FDA UNII
362NTC92GU
Created by admin on Sat Dec 16 11:36:50 GMT 2023 , Edited by admin on Sat Dec 16 11:36:50 GMT 2023
PRIMARY
PUBCHEM
57343743
Created by admin on Sat Dec 16 11:36:50 GMT 2023 , Edited by admin on Sat Dec 16 11:36:50 GMT 2023
PRIMARY
CAS
852055-88-0
Created by admin on Sat Dec 16 11:36:50 GMT 2023 , Edited by admin on Sat Dec 16 11:36:50 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY
Platrol has demonstrated 40% more efficacy and negligible toxicity resulting in higher therapeutic index compared to Aspirin, Clopidogrel and other anti-platelet drugs in clinical trials. Surprisingly, its inherent sustained release property makes Platrol even better as a long-term cardio-protective drug. Pioneering studies by Garret Fitzgerald at the University of Pennsylvania and other scientists in the 80's have shown that a controlled release formulation of Aspirin at the correct release rate will result in sustained specific irreversible acetylation of platelets as they pass through the portal circulation. This will enhance action of Aspirin in endothelium, but mitigating its anti-Aspirin like activity if released into the systemic circulation.